Multidisciplinary approach to congenital Toxoplasma infection: An Italian nationwide survey

Lina R. Tomasoni, Valeria Meroni, Carlo Bonfanti, Lina Bollani, Paolo Lanzarini, Tiziana Frusca, Francesco Castelli

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Italy provides a free voluntary serological screening for toxoplasmosis in pregnancy supported by public health system, as there is an estimated congenital toxoplasmosis rate of 1-2/10,000. The aim of this study was to make an inventory of diagnostic and therapeutic protocols in use in Italy in the absence of a national guideline. A semistructured questionnaire was distributed to AMCLI (Italian Association of Clinical Microbiologists) members who were asked to involve other specialists to fill in the form. Data from 26 centers show: a) a general use of the IgG avidity test to solve diagnosis in IgG/IgM positive, pregnant women; b) a widespread attitude to spyramicin antenatal treatment in suspected, unconfirmed maternal infection; c) avoidance of invasive antenatal diagnosis only in suspected early or late (>24 weeks), even confirmed, maternal infection d) fetal diagnosis performed by PCR assays on amniotic fluid; e) variability of both indications and dosage of pyrimethamine-sulfadiazine (P-S) as fetal treatment; f) use of comparative mother and newborn IgG/IgM Immuneblot in most centers; g) no diagnostic tests performed on placenta and cord blood; h) spyramicin is no longer used in congenital infections; i) no P-S-based treatment for children at high risk of congenital infection (late maternal infection) in the absence of diagnosis. As there is the opportunity to test pregnant women for Toxoplasma gondii infection in Italy free of charge, standardized diagnostic and therapeutic national guidelines would focus on a more uniform approach.

Original languageEnglish
Pages (from-to)347-354
Number of pages8
JournalNew Microbiologica
Volume37
Issue number3
Publication statusPublished - 2014

Fingerprint

Congenital Toxoplasmosis
Mothers
Italy
Sulfadiazine
Pyrimethamine
Infection
Immunoglobulin G
Toxoplasmosis
Immunoglobulin M
Pregnant Women
Guidelines
Therapeutics
Amniotic Fluid
Prenatal Diagnosis
Fetal Blood
Routine Diagnostic Tests
Placenta
Public Health
Surveys and Questionnaires
Newborn Infant

Keywords

  • Diagnosis
  • Pregnancy
  • Toxoplasma
  • Treatment

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Tomasoni, L. R., Meroni, V., Bonfanti, C., Bollani, L., Lanzarini, P., Frusca, T., & Castelli, F. (2014). Multidisciplinary approach to congenital Toxoplasma infection: An Italian nationwide survey. New Microbiologica, 37(3), 347-354.

Multidisciplinary approach to congenital Toxoplasma infection : An Italian nationwide survey. / Tomasoni, Lina R.; Meroni, Valeria; Bonfanti, Carlo; Bollani, Lina; Lanzarini, Paolo; Frusca, Tiziana; Castelli, Francesco.

In: New Microbiologica, Vol. 37, No. 3, 2014, p. 347-354.

Research output: Contribution to journalArticle

Tomasoni, LR, Meroni, V, Bonfanti, C, Bollani, L, Lanzarini, P, Frusca, T & Castelli, F 2014, 'Multidisciplinary approach to congenital Toxoplasma infection: An Italian nationwide survey', New Microbiologica, vol. 37, no. 3, pp. 347-354.
Tomasoni, Lina R. ; Meroni, Valeria ; Bonfanti, Carlo ; Bollani, Lina ; Lanzarini, Paolo ; Frusca, Tiziana ; Castelli, Francesco. / Multidisciplinary approach to congenital Toxoplasma infection : An Italian nationwide survey. In: New Microbiologica. 2014 ; Vol. 37, No. 3. pp. 347-354.
@article{95775605fe02418ca92aee2209641deb,
title = "Multidisciplinary approach to congenital Toxoplasma infection: An Italian nationwide survey",
abstract = "Italy provides a free voluntary serological screening for toxoplasmosis in pregnancy supported by public health system, as there is an estimated congenital toxoplasmosis rate of 1-2/10,000. The aim of this study was to make an inventory of diagnostic and therapeutic protocols in use in Italy in the absence of a national guideline. A semistructured questionnaire was distributed to AMCLI (Italian Association of Clinical Microbiologists) members who were asked to involve other specialists to fill in the form. Data from 26 centers show: a) a general use of the IgG avidity test to solve diagnosis in IgG/IgM positive, pregnant women; b) a widespread attitude to spyramicin antenatal treatment in suspected, unconfirmed maternal infection; c) avoidance of invasive antenatal diagnosis only in suspected early or late (>24 weeks), even confirmed, maternal infection d) fetal diagnosis performed by PCR assays on amniotic fluid; e) variability of both indications and dosage of pyrimethamine-sulfadiazine (P-S) as fetal treatment; f) use of comparative mother and newborn IgG/IgM Immuneblot in most centers; g) no diagnostic tests performed on placenta and cord blood; h) spyramicin is no longer used in congenital infections; i) no P-S-based treatment for children at high risk of congenital infection (late maternal infection) in the absence of diagnosis. As there is the opportunity to test pregnant women for Toxoplasma gondii infection in Italy free of charge, standardized diagnostic and therapeutic national guidelines would focus on a more uniform approach.",
keywords = "Diagnosis, Pregnancy, Toxoplasma, Treatment",
author = "Tomasoni, {Lina R.} and Valeria Meroni and Carlo Bonfanti and Lina Bollani and Paolo Lanzarini and Tiziana Frusca and Francesco Castelli",
year = "2014",
language = "English",
volume = "37",
pages = "347--354",
journal = "New Microbiologica",
issn = "1121-7138",
publisher = "Luigi Ponzio e figlio Editori",
number = "3",

}

TY - JOUR

T1 - Multidisciplinary approach to congenital Toxoplasma infection

T2 - An Italian nationwide survey

AU - Tomasoni, Lina R.

AU - Meroni, Valeria

AU - Bonfanti, Carlo

AU - Bollani, Lina

AU - Lanzarini, Paolo

AU - Frusca, Tiziana

AU - Castelli, Francesco

PY - 2014

Y1 - 2014

N2 - Italy provides a free voluntary serological screening for toxoplasmosis in pregnancy supported by public health system, as there is an estimated congenital toxoplasmosis rate of 1-2/10,000. The aim of this study was to make an inventory of diagnostic and therapeutic protocols in use in Italy in the absence of a national guideline. A semistructured questionnaire was distributed to AMCLI (Italian Association of Clinical Microbiologists) members who were asked to involve other specialists to fill in the form. Data from 26 centers show: a) a general use of the IgG avidity test to solve diagnosis in IgG/IgM positive, pregnant women; b) a widespread attitude to spyramicin antenatal treatment in suspected, unconfirmed maternal infection; c) avoidance of invasive antenatal diagnosis only in suspected early or late (>24 weeks), even confirmed, maternal infection d) fetal diagnosis performed by PCR assays on amniotic fluid; e) variability of both indications and dosage of pyrimethamine-sulfadiazine (P-S) as fetal treatment; f) use of comparative mother and newborn IgG/IgM Immuneblot in most centers; g) no diagnostic tests performed on placenta and cord blood; h) spyramicin is no longer used in congenital infections; i) no P-S-based treatment for children at high risk of congenital infection (late maternal infection) in the absence of diagnosis. As there is the opportunity to test pregnant women for Toxoplasma gondii infection in Italy free of charge, standardized diagnostic and therapeutic national guidelines would focus on a more uniform approach.

AB - Italy provides a free voluntary serological screening for toxoplasmosis in pregnancy supported by public health system, as there is an estimated congenital toxoplasmosis rate of 1-2/10,000. The aim of this study was to make an inventory of diagnostic and therapeutic protocols in use in Italy in the absence of a national guideline. A semistructured questionnaire was distributed to AMCLI (Italian Association of Clinical Microbiologists) members who were asked to involve other specialists to fill in the form. Data from 26 centers show: a) a general use of the IgG avidity test to solve diagnosis in IgG/IgM positive, pregnant women; b) a widespread attitude to spyramicin antenatal treatment in suspected, unconfirmed maternal infection; c) avoidance of invasive antenatal diagnosis only in suspected early or late (>24 weeks), even confirmed, maternal infection d) fetal diagnosis performed by PCR assays on amniotic fluid; e) variability of both indications and dosage of pyrimethamine-sulfadiazine (P-S) as fetal treatment; f) use of comparative mother and newborn IgG/IgM Immuneblot in most centers; g) no diagnostic tests performed on placenta and cord blood; h) spyramicin is no longer used in congenital infections; i) no P-S-based treatment for children at high risk of congenital infection (late maternal infection) in the absence of diagnosis. As there is the opportunity to test pregnant women for Toxoplasma gondii infection in Italy free of charge, standardized diagnostic and therapeutic national guidelines would focus on a more uniform approach.

KW - Diagnosis

KW - Pregnancy

KW - Toxoplasma

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84906500953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906500953&partnerID=8YFLogxK

M3 - Article

C2 - 25180849

AN - SCOPUS:84906500953

VL - 37

SP - 347

EP - 354

JO - New Microbiologica

JF - New Microbiologica

SN - 1121-7138

IS - 3

ER -